Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2026)
Recursion Pharmaceuticals (RXRX) recorded Research & Development of $89.61 million in Q2 2026, down 30.3% from $128.64 million a year earlier but up 2.0% from the prior quarter.
Powered by 
Analysis
Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2026) Analysis & Trends
On a TTM basis, Recursion Pharmaceuticals' Research & Development came in at $394.51 million as of Jun 30, 2026, down 8.5% year-over-year; for FY2025, it was $475.27 million, up 51.2% from FY2024.
- Annual Research & Development has increased for six straight years, with a five-year compound annual growth rate of 49.7% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $314.42 million in FY2024 (+30.3%), $241.23 million in FY2023 (+54.9%), $155.7 million in FY2022 (+15.1%) and $135.27 million in FY2021 (+113.6%).
- Quarterly Research & Development has ranged from $32.44 million in Q1 2022 to $129.63 million in Q1 2025 over the past five years.
- On a year-over-year basis, Research & Development has declined for three consecutive quarters, with growth averaging 26.4% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 133.3% in Q4 2021, against a decline of 32.2% in Q1 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at $87.9 million (Q1 2026), $95.94 million (Q4 2025) and $121.06 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Recursion Pharmaceuticals | 1.98 Bn | -627.04 Mn | -3.82 Mn | 89.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 89.61 Mn |
| Mar 31, 2026 | 87.90 Mn |
| Dec 31, 2025 | 95.94 Mn |
| Sep 30, 2025 | 121.06 Mn |
| Jun 30, 2025 | 128.64 Mn |
| Mar 31, 2025 | 129.63 Mn |
| Dec 31, 2024 | 98.33 Mn |
| Sep 30, 2024 | 74.60 Mn |
| Jun 30, 2024 | 73.93 Mn |
| Mar 31, 2024 | 67.56 Mn |
| Dec 31, 2023 | 69.48 Mn |
| Sep 30, 2023 | 70.01 Mn |
| Jun 30, 2023 | 55.06 Mn |
| Mar 31, 2023 | 46.68 Mn |
| Dec 31, 2022 | 43.98 Mn |
| Sep 30, 2022 | 40.84 Mn |
| Jun 30, 2022 | 38.44 Mn |
| Mar 31, 2022 | 32.44 Mn |
| Dec 31, 2021 | 48.29 Mn |
| Sep 30, 2021 | 33.25 Mn |
API Access
Recursion Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RXRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RXRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RXRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();